IMCI works with licensed partners on cannabinoid supply models tailored to local market needs. These can include finished dosage forms, magistral preparations, premix, and private-label products.

Yes. IMCI’s partnership approach is designed to match product format and supply model to the requirements of each local market and partner.

IMCI primarily develops cannabinoid formulations for licensed partners in regulated medical cannabis markets. The company also offers Ci adult-use products and private-label opportunities in permitted markets through licensed partners.